Cintas Corporation Announces 15.4% Increase in Quarterly Cash Dividend
Any future dividend declarations, including the amount of any dividends, are at the discretion of the Board of Directors and dependent upon then-existing conditions, including the Company's operating results and financial condition, capital requirements, contractual restrictions, business prospects and other factors that the Board of Directors may deem relevant.
Todd M. Schneider, Cintas' President, and Chief Executive Officer, stated, 'We achieved record revenue and profit in our fiscal 2025. We grew sales and profit again, which is now 54 out of the last 56 years. Due to our excellent financial results and strong financial position, we are increasing our quarterly dividend. The dividend, accompanied by our share buyback program, continues to demonstrate our commitment to increasing shareholder value.'
Cintas
Cintas Corporation helps more than one million businesses of all types and sizes get Ready™ to open their doors with confidence every day by providing products and services that help keep their customers' facilities and employees clean, safe and looking their best. With offerings including uniforms, mats, mops, towels, restroom supplies, workplace water services, first aid and safety products, eye-wash stations, safety training, fire extinguishers, sprinkler systems and alarm service, Cintas helps customers get Ready for the Workday®. Headquartered in Cincinnati, Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS and is a component of both the Standard & Poor's 500 Index and Nasdaq-100 Index.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why SoundHound AI's (SOUN) Amelia Acquisition Could Pay Off in the Long Run
SoundHound AI, Inc. (NASDAQ:SOUN) is one of the AI Stocks Analysts Are Watching Closely. On August 11, Ladenburg Thalmann analyst Glenn Mattson upgraded the stock from Neutral to Buy with a price target of $16.00 (from $9.00). The rating upgrade comes after Soundhound posted second-quarter revenue well above expectations driven by its large contract wins. According to the firm, momentum in core verticals is helping offset previous concerns about low-margin contracts from the Amelia acquisition. These are anticipated to be phased out over the next 18 months. The firm also believes that SoundHound is building a broader platform that may link automotive, restaurant and enterprise customers into a voice-enabled ecosystem. This will in turn create lead-generation revenue streams. A Wall Street analyst reviewing stock information on a computer, examining data points for a new investment opportunity. 'We upgrade shares to Buy and raise our PT to $16 (from $9). We continue to view Voice as one of the key early applications for AI systems. The company is a leader in this space and is adding significant utility for enterprises looking to adopt AI functionality. The Amelia acquisition still needs further integration but is providing solid benefits in terms of scale, new lead generation, and an entry into the enterprise. While valuation remains elevated, the growth and scale justify that premium, in our view. We now use a 22x multiple on our new 2027 estimate to achieve our $16 PT. This is justified by the rule of 40 peer set found in the body of the report.' SoundHound AI, Inc. (NASDAQ:SOUN) is a voice artificial intelligence company offering voice AI solutions to businesses. While we acknowledge the potential of SOUN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Applied Materials (NASDAQ:AMAT) Stock Drops 11% Due to Guidance
Semiconductor machinery manufacturer Applied Materials (NASDAQ:AMAT) beat Wall Street's revenue expectations in Q2 CY2025, with sales up 7.7% year on year to $7.30 billion. On the other hand, next quarter's revenue guidance of $6.7 billion was less impressive, coming in 8.2% below analysts' estimates. Its non-GAAP profit of $2.48 per share was 5.1% above analysts' consensus estimates. Is now the time to buy Applied Materials? Find out in our full research report. Applied Materials (AMAT) Q2 CY2025 Highlights: Revenue: $7.30 billion vs analyst estimates of $7.22 billion (7.7% year-on-year growth, 1.2% beat) Adjusted EPS: $2.48 vs analyst estimates of $2.36 (5.1% beat) Adjusted Operating Income: $2.25 billion vs analyst estimates of $2.16 billion (30.7% margin, 4% beat) Revenue Guidance for Q3 CY2025 is $6.7 billion at the midpoint, below analyst estimates of $7.30 billion Adjusted EPS guidance for Q3 CY2025 is $2.11 at the midpoint, below analyst estimates of $2.38 Operating Margin: 30.6%, up from 28.7% in the same quarter last year Free Cash Flow Margin: 28.1%, down from 30.8% in the same quarter last year Inventory Days Outstanding: 141, down from 142 in the previous quarter Market Capitalization: $152.5 billion 'Applied Materials delivered record performance in our third fiscal quarter, and we are on track to deliver our sixth consecutive year of revenue growth in fiscal 2025,' said Gary Dickerson, President and CEO. Company Overview Founded in 1967 as the first company to develop tools for other businesses in the semiconductor industry, Applied Materials (NASDAQ:AMAT) is the largest provider of semiconductor wafer fabrication equipment. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Applied Materials grew its sales at a solid 12% compounded annual growth rate. Its growth beat the average semiconductor company and shows its offerings resonate with customers, a helpful starting point for our analysis. Semiconductors are a cyclical industry, and long-term investors should be prepared for periods of high growth followed by periods of revenue contractions. Long-term growth is the most important, but short-term results matter for semiconductors because the rapid pace of technological innovation (Moore's Law) could make yesterday's hit product obsolete today. Applied Materials's recent performance shows its demand has slowed as its annualized revenue growth of 3.8% over the last two years was below its five-year trend. This quarter, Applied Materials reported year-on-year revenue growth of 7.7%, and its $7.30 billion of revenue exceeded Wall Street's estimates by 1.2%. Beyond the beat, this marks 6 straight quarters of growth, showing that the current upcycle has had a good run - a typical upcycle usually lasts 8-10 quarters. Company management is currently guiding for a 4.9% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 4.5% over the next 12 months, similar to its two-year rate. This projection is underwhelming and indicates its newer products and services will not accelerate its top-line performance yet. At least the company is tracking well in other measures of financial health. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Product Demand & Outstanding Inventory Days Inventory Outstanding (DIO) is an important metric for chipmakers, as it reflects a business' capital intensity and the cyclical nature of semiconductor supply and demand. In a tight supply environment, inventories tend to be stable, allowing chipmakers to exert pricing power. Steadily increasing DIO can be a warning sign that demand is weak, and if inventories continue to rise, the company may have to downsize production. This quarter, Applied Materials's DIO came in at 141, which is 2 more days than its five-year average. These numbers suggest that despite the recent decrease, the company's inventory levels are slightly above the long-term average. Key Takeaways from Applied Materials's Q2 Results It was good to see Applied Materials beat analysts' EPS expectations this quarter. We were also glad its adjusted operating income outperformed Wall Street's estimates. On the other hand, its revenue and EPS guidance for next quarter both missed. This is weighing on shares, and the stock traded down 11% to $167.40 immediately after reporting. Big picture, is Applied Materials a buy here and now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
